Recurrence and survival analysis of resected soft tissue sarcomas of pelvic retroperitoneal structures

BackgroundThe purpose is to determine the clinicopathologic factors related to survival and recurrence of primary resected pelvic soft tissue sarcomas (STS). MethodsDemographic/clinical variables were recorded. ResultsThirty-five pts were identified. Median follow-up was 24.2 months. There were 23 (65.7%) high/intermediate-grade and 12 (34.3%) low-grade tumors included in the final analysis. Eight patients (22.9%) received neoadjuvant therapy. Margins were grossly negative in 27 (77.1%, 17-R0, 10-R1) and grossly positive (R2) in 8 (22.9%). Adjuvant therapy was used in 13 patients (37.1%). The 2- and 3-year RFS was 56.5% and 51.3%, with 14 patients recurring at a median time of 16 months (6-local, 8-distant). All distant recurrences were in high-grade tumors. There were no differences in RFS for margins (R0 vs. R1), neoadjuvant/adjuvant therapy, size (10 vs. <10cm) or gender. High/intermediate-grade tumors had worse RFS (P<0.008). The 2- and 3-year OS was 80.9%. OS was improved for R0/R1 resection (P<0.001). Resection to R0/R1 margin was a significant predictor of improved OS (P=0.001). ConclusionsHigh/intermediate-grade lesions were associated with worse OS and RFS. Resection to gross negative margins was the only independent predictor of OS. Adjuvant therapy may be reserved for high-grade lesions due to increased metastatic potential. J. Surg. Oncol. 2016;113:103-107. (c) 2016 Wiley Periodicals, Inc.